Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NextCure, Inc.NXTC · Entity 7461 | Chief Medical Officer | January 30, 2026 | February 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NextCure, Inc.
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.85 · Expires 2036-01-29 | Direct | 14,670 |
Reported balance
After 2026-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 14,670 · Balance 14,670 F1: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Feb 3, 2026 16:07 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,670 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0000905148-26-000477 · form4.xml · derivative · entry 1 Guha Udayan · CIK 0002054923 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,670 Underlying: Common Stock · 14,670 shares Expires 2036-01-29 F1 · derivative.exercise_date: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.